HR+/HER2- Breast Cancer Brain MetastasesPhase 1/2NCT04923542
Radiosurgery + Abemaciclib
SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
What the film says
When stomach or esophageal cancer spreads across the lining of the abdomen, chemotherapy reaches it poorly, and survival is measured in months.
The idea: put engineered T cells directly into the abdominal cavity, and armor them against the tumor's off switch.
Most of these tumors carry mesothelin on their surface. At Memorial Sloan Kettering, a patient's own T cells receive a receptor for mesothelin, tuned to fire without exhausting, plus a decoy PD-1 receptor: it catches the tumor's shut-down signal but cannot pass it on. The cells are infused into the peritoneal cavity, where the disease is, rather than into a vein.
An early dose-finding study for metastatic esophagogastric adenocarcinoma with peritoneal spread. Geoffrey Ku leads it. Public record; not medical advice.
Sources behind this film
Peritoneal carcinomatosis in EG cancer: poor drug penetration, short survival; Mesothelin ≥25% by IHC required; Intraperitoneal infusion; manufactured at MSK's Center for Cell Engineering; Geoffrey Ku; MSK; enrollment 18
Feucht J. Nat Med, 2019
M28z1XX = mesothelin CAR with calibrated CD3ζ signaling ("tuned to fire without exhausting")
Cherkassky L. J Clin Invest, 2016
PD1DNR = PD-1 dominant-negative receptor ("decoy that cannot pass the signal on")
The drug
Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.
The study
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.